Somerset-based Catalent on Wednesday announced that, effective July 1, Alessandro Maselli will be the company’s next CEO and president, succeeding John Chiminski. Maselli will also join the company’s board of directors upon assuming his new role.
Maselli, who has more than 11 years of experience at Catalent, is currently the president and chief operating officer.
Chiminski, currently chair and CEO, will remain in his present role until July 1, when he will assume the position of executive chair of the board.
“I am grateful and humbled to have had the opportunity to lead Catalent over the past 12 years, and I’m pleased to congratulate Alessandro, an experienced leader who has been critical to Catalent’s success,” Chiminski said.
According to Chiminski, Maselli was instrumental in ensuring that Catalent was prepared to manufacture over 1 billion COVID-19 vaccine doses that were successfully delivered in record time during 2021.
“I am deeply honored to have the opportunity to succeed John as Catalent’s chief executive officer,” said Maselli. “Catalent plays a critical role in the global health care ecosystem, and, for the past decade, I’ve been privileged to work alongside our company’s talented, dedicated employees to drive our business and ensure the timely and reliable supply of thousands of important medicines to patients.”
Since joining Catalent in October 2010, Maselli has held key positions — from site leadership positions at two important manufacturing facilities in Italy and the United Kingdom to senior positions in global operations, corporate oversight and strategy.
He was appointed Catalent’s president and COO in February 2019.
Prior to Catalent, Maselli held leadership roles at Alstom and SGS. From 1998 to 2006, he held roles of increasing responsibility, from process engineer to operations director at ABB Group. Maselli began his career as an automation systems engineer in the food industry.
